Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra (Q43290572)
Jump to navigation
Jump to search
scientific article published on 17 August 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra |
scientific article published on 17 August 2009 |
Statements
1 reference
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthra (English)
1 reference
1 reference
Natalia V Bogdanova
1 reference
Joseph A Sparano
1 reference
Anatoly N Makhson
1 reference
Sergei A Tjulandin
1 reference
Olga I Balashova
1 reference
George M Manikhas
1 reference
Gennadiy P Oliynychenko
1 reference
Valery A Chatikhine
1 reference
Sen H Zhuang
1 reference
Liang Xiu
1 reference
Zhilong Yuan
1 reference
Wayne R Rackoff
1 reference
17 August 2009
1 reference
1 reference
Identifiers
1 reference